There are increasing calls for the application of systems ergonomics methods in healthcare, although evidence for their utility and uptake is limited. In this study, 67 Australian healthcare workers participated in a six-month longitudinal study where they were trained to apply the AcciMap adverse event analysis and Net-HARMS risk assessment methods. Data were gathered in line with the RE-AIM (Reach, Efficacy, Adoption, Implementation, and Maintenance) evaluation framework, including rates of organisational uptake and method validity, perceived workload, usability, and barriers and facilitators to use in practice. Overall RE-AIM ratings for AcciMap were relatively high, and more moderate for Net-HARMS. Time constraints was the most frequently identified barrier to the use of both methods in practice, while there was more organisational resistance to Net-HARMS uptake. Facilitators for the use of both methods include providing quality training and mentorship, additional time and software resources, and dedicated job roles.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00140139.2024.2423170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.
View Article and Find Full Text PDFIt is well recognised that Alzheimer's disease and related dementia disorders (ADRD) are associated with very high societal costs. The total global costs of dementia have been estimated to over 1.3 trillion US$ annually (Wimo, Seeher et al.
View Article and Find Full Text PDFIntroduction: The United States is undergoing a demographic shift with increasing proportions of older adults. Currently, one in three older adults pass away with a form of Alzheimer's disease or related dementias (ADRD). This figure is higher in underrepresented and underserved groups including older adults in rural Appalachian communities.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Seattle, WA, USA.
Background: Incretin receptor agonists (IRAs) are synthetic peptides that have beneficial effects within the brain. We investigated IRA brain uptake following two routes of delivery: across the blood-brain barrier (BBB) and following intranasal (IN) delivery.
Method: Radiolabeled IRAs were delivered intravenously or intranasally into CD-1 mice and uptake by or distribution throughout the brain was assessed.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar, Punjab, India.
Background: Alzheimer's disease (AD) is a type of degenerative disorder that affects the brain. There are various herbal drugs that have been tested for their effectiveness in treating AD, and chrysin is one of them. Chrysin is a polyphenolic flavonoid that has several neuroprotective effects, including reducing the levels of AChE enzyme, accumulated amyloid β, oxidative stress, and neuroinflammation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!